The same is true for the cytostatic effects, because despite potential inhibition of OCT 1/3 and OATP1A2-mediate uptake of doxorubicin into tumor cells by CrEL, paclitaxel adds synergistically to the anticancer activity. Here, SLCO1A2 is linked to neoplasm.